

PT. PFIZER INDONESIA
Local Product Document

Generic Name: Methylprednisolone tablets

Trade Name: **MEDROL®**


CDS Effective Date: June 26, 2019

Supersedes: January 03, 2018

DESCRIPTION

MEDROL® Tablets contain methylprednisolone, which is a glucocorticoid. Glucocorticoids are adrenocortical steroids but naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Methylprednisolone occurs as a white to practically white, odorless, crystalline powder. It is sparingly soluble in alcohol, in dioxane, and in methanol, slightly soluble in acetone, and in chloroform, and very slightly soluble in ether. It is practically insoluble in water.

The chemical name for methylprednisolone is pregna-1, 4-diene-3, 20-dione, 11, 17, 21-trihydroxy-6-methyl-, (6 α , 11 β) - and the molecular weight is 374.48. The structural formula is represented below:



Each MEDROL® Tablet for oral administrations contains 4 mg and 16 mg of methylprednisolone.

PHARMACOLOGICAL PROPERTIES

Pharmacodynamic properties

Naturally occurring glucocorticoids (hydrocortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorder of many organ systems. It has greater anti-inflammatory potency than prednisolone and less tendency than prednisolone to induce sodium and water retention. The relative potency of methylprednisolone to hydrocortisone is at least four to one.

Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.

Pharmacokinetic properties

Methylprednisolone pharmacokinetics is linear, independent of route of administration.

Absorption:

Methylprednisolone is rapidly absorbed and the maximum plasma methylprednisolone concentration is achieved around 1.5 to 2.3 hours across doses following oral administration in normal healthy adults. The absolute bioavailability of methylprednisolone in normal healthy subjects is generally high (82% to 89%) following oral administration.

Distribution:

Methylprednisolone is widely distributed into the tissues, crosses the blood-brain barrier, and is secreted in breast milk. Its apparent volume of distribution is approximately 1.4 L/kg. The plasma protein binding of methylprednisolone in humans is approximately 77%.

Metabolism:

In humans, Methylprednisolone is metabolized in the liver to inactive metabolites, the major ones are 20 α -hydroxymethylprednisolone and 20 β -hydroxymethylprednisolone. Metabolism in the liver occurs primarily via the CYP3A4 enzyme. For a list of drug interactions based on CYP3A4-mediated metabolism, see section **DRUG INTERACTIONS**.

Methylprednisolone, like many CYP3A4 substrates, may also be a substrate for the ATP-binding cassette (ABC) transport protein p-glycoprotein, influencing tissue distribution and interactions with other medicines.

Elimination:

The mean elimination half-life for total methylprednisolone is in the range of 1.8 to 5.2 hours.

Methylprednisolone clearance is altered by concurrent administration of troleandomycin, erythromycin, rifampicin, anticonvulsants and theophylline.

No dosing adjustments are necessary in renal failure.

Preclinical safety data

The non-clinical database, in combination with evidence of safety gleaned from years of clinical experience and post-marketing surveillance, supports the safety of methylprednisolone tablets as a potent anti-inflammatory agent in short-term inflammatory disorders.

Based on conventional studies of safety pharmacology, repeated-dose toxicity no unexpected hazards were identified. The toxicities seen in the repeated-dose studies are those expected to occur with continued exposure to exogenous adrenocortical steroids.

Carcinogenic potential:

Methylprednisolone has not been formally evaluated in rodent carcinogenicity studies. Variable results have been obtained with other glucocorticoids tested for carcinogenicity in mice and rats. However, published data indicate that several related glucocorticoids including budesonide, prednisolone, and triamcinolone acetonide can increase the incidence of hepatocellular adenomas

and carcinomas after oral administration in drinking water to male rats. These tumorigenic effects occurred at doses which were less than the typical clinical doses on a mg/m² basis.

Mutagenic potential:

Methylprednisolone has not been formally evaluated for genotoxicity. However, methylprednisolone sulfonate, which is structurally similar to methylprednisolone, was not mutagenic with or without metabolic activation in *Salmonella typhimurium* at 250 to 2,000 µg/plate, or in a mammalian cell gene mutation assay using Chinese hamster ovary cells at 2,000 to 10,000 µg/mL. Methylprednisolone suleptanate did not induce unscheduled DNA synthesis in primary rat hepatocytes at 5 to 1,000 µg/mL. Moreover, a review of published data indicates that prednisolone farnesylate (PNF), which is structurally similar to methylprednisolone, was not mutagenic with or without metabolic activation in *Salmonella typhimurium* and *Escherichia coli* strains at 312 to 5,000 µg/plate. In a Chinese hamster fibroblast cell line, PNF produced a slight increase in the incidence of structural chromosomal aberrations with metabolic activation at the highest concentration tested 1,500 µg/mL.

Reproductive toxicity:

Corticosteroids have been shown to reduce fertility when administered to rats. Male rats were administered corticosterone at doses of 0, 10, and 25 mg/kg/day by subcutaneous injection once daily for 6 weeks and mated with untreated females. The high dose was reduced to 20 mg/kg/day after Day 15. Decreased copulatory plugs were observed, which may have been secondary to decreased accessory organ weight. The numbers of implantations and live fetuses were reduced.

Corticosteroids have been shown to be teratogenic in many species when given in doses equivalent to the human dose. In animal reproduction studies, glucocorticoids, such as methylprednisolone have been shown to increase the incidence of malformations (cleft palate, skeletal malformations), embryo-fetal lethality (e.g., increase in resorptions), and intra-uterine growth retardation.

INDICATIONS

MEDROL[®] Tablets are indicated in the following conditions:

1. Endocrine Disorders

Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance.

- Congenital adrenal hyperplasia
- Non-suppurative thyroiditis
- Hypercalcemia associated with cancer

2. Rheumatic Disorders

As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:

- Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).
- Ankylosing spondylitis
- Psoriatic arthritis
- Acute and subacute bursitis

- Epicondylitis
- Synovitis of osteoarthritis
- Acute gouty arthritis
- Acute non-specific tenosynovitis
- Post-traumatic osteoarthritis

3. Collagen Diseases

During an exacerbation or as maintenance therapy in selected cases of:

- Systemic lupus erythematosus
- Systemic dermatomyositis (polymyositis)
- Acute rheumatic carditis

4. Dermatologic Diseases

- Bullous dermatitis herpetiformis
- Severe erythema multiforme (Stevens-Johnson syndrome)
- Severe seborrheic dermatitis
- Exfoliative dermatitis
- Pemphigus
- Mycosis fungoides
- Severe psoriasis

5. Allergic States

Control of severe or incapacitating allergic condition intractable to adequate trials of conventional treatments:

- Seasonal or perennial allergic rhinitis
- Drug hypersensitivity reactions
- Serum sickness
- Bronchial asthma
- Contact dermatitis
- Atopic dermatitis

6. Ophthalmic Diseases

Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as:

- Allergic corneal marginal ulcers
- Herpes zoster ophthalmicus
- Anterior segment inflammation
- Diffuse posterior uveitis and choroiditis
- Sympathetic ophthalmia
- Keratitis
- Allergic conjunctivitis
- Optic neuritis
- Chorioretinitis
- Iritis and iridocyclitis

7. Respiratory Diseases

- Symptomatic sarcoidosis
- Berylliosis
- Loeffler's syndrome not manageable by other means

- Fulminating or disseminated pulmonary tuberculosis when use concurrently with appropriate antituberculous chemotherapy
- Aspiration pneumonitis

8. Hematologic Disorders

- Idiopathic thrombocytopenic purpura in adults
- Secondary thrombocytopenia in adults
- Acquired (autoimmune) hemolytic anemia
- Erythroblastopenia (RBC anemia)
- Congenital (erythroid) hypoplastic anemia

9. Neoplastic Diseases

For palliative management of:

- Leukemias and lymphomas in adults
- Acute leukemia of childhood

10. Edematous States

To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, or the idiopathic type or that due to lupus erythematosus.

11. Gastrointestinal Diseases

To tide the patient over a critical period of the diseases in:

- Ulcerative colitis
- Regional enteritis

12. Nervous System

Acute exacerbation of multiple sclerosis.

13. Miscellaneous

- Tuberculous meningitis with subarachnoid block of impending block when used concurrently with appropriate antituberculous chemotherapy.
- Trichinosis with neurologic or myocardial involvement.

CONTRAINDICATIONS

Systemic fungal infections and known hypersensitivity to components.

Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids.

WARNINGS

Immunosuppressant Effects/Increased Susceptibility to Infections

Corticosteroids may increase susceptibility to infection, may mask some sign of infection, and new infections may appear during their use. There may be decreased resistance and inability to localized infection when corticosteroids are used.

Persons who are on drugs which suppress the immune system are more susceptible to infections than healthy individuals. Chicken pox and measles, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids.

While on corticosteroid therapy, patients should not be vaccinated against smallpox. Other immunization procedure should not be undertaken in patients who are on corticosteroids, especially on high doses, because of possible hazards of neurological complication and lack of antibody response.

The use of MEDROL[®] Tablets in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with appropriate antituberculosis regimen.

If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation if necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.

The role of corticosteroids in septic shock has been controversial, with early studies reporting both beneficial and detrimental effects. More recently, supplemental corticosteroids have been suggested to be beneficial in patients with established septic shock who exhibit adrenal insufficiency. However, their routine use in septic shock is not recommended and a systematic review concluded that short-course, high-dose corticosteroids did not support their use. However, meta-analyses and a review suggest that longer courses (5-11 days) of low-dose corticosteroids might reduce mortality, especially in patients with vasopressor-dependent septic shock.

Immune System

Allergic reactions (e.g., angioedema) may occur.

Because rare instances of skin reactions and anaphylactic/anaphylactoid reactions have occurred in patients receiving corticosteroid therapy, appropriate precautionary measures should be taken prior to administration, especially when the patient has a history of allergy to any drug.

This medicine contains lactose produced from cow's milk. Caution should be exercised in patients with a known or suspected hypersensitivity to cow's milk or its components or other dairy products because it may contain trace amounts of milk ingredients.

Endocrine

In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.

Pharmacologic doses of corticosteroids administered for prolonged periods may result in hypothalamic-pituitary-adrenal (HPA) suppression (secondary adrenocortical insufficiency).

The degree and duration of adrenocortical insufficiency produced is variable among patients and depends on the dose, frequency, time of administration, and duration of glucocorticoid therapy. This effect may be minimized by the use of alternate-day therapy (See section **POSLOGY AND METHOD OF ADMINISTRATION**.)

In addition, acute adrenal insufficiency leading to a fatal outcome may occur if glucocorticoids are withdrawn abruptly.

Drug-induced adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation stress occurring during that period, hormone therapy should be reinstituted.

A steroid “withdrawal syndrome,” seemingly unrelated to adrenocortical insufficiency, may also occur following abrupt discontinuance of glucocorticoids. This syndrome includes symptoms such as: anorexia, nausea, vomiting, lethargy, headache, fever, joint pain, desquamation, myalgia, weight loss, and/or hypotension. These effects are thought to be due to the sudden change in glucocorticoid concentration rather than to low corticosteroid levels.

Because glucocorticoids can produce or aggravate Cushing’s syndrome, glucocorticoids should be avoided in patients with Cushing’s disease.

There is an enhanced effect of corticosteroids on patients with hypothyroidism.

Metabolism and Nutrition

Corticosteroids, including methylprednisolone, can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term corticosteroid therapy to diabetes mellitus.

Particular care is required when considering the use of systemic corticosteroids in patients with Diabetes mellitus (or a family history of diabetes) and frequent patient monitoring is necessary.

Psychiatric

Psychic derangements may appear when corticosteroids are used ranging from euphoria, insomnia, mood swings, personality changes, and severe depression to frank psychotic manifestation. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.

Potentially severe psychiatric adverse reactions may occur with systemic steroids (See section **ADVERSE REACTIONS**). Symptoms typically emerge within a few days or weeks of starting treatment. Most reactions recover after either dose reduction or withdrawal, although specific treatment may be necessary. Psychological effects have been reported upon withdrawal of corticosteroids; the frequency is unknown. Patients/caregivers should be encouraged to seek medical attention if psychological symptoms develop in the patient, especially if depressed mood or suicidal ideation is suspected. Patients/caregivers should be alert to possible psychiatric disturbances that may occur either during or immediately after dose tapering/withdrawal of systemic steroids.

Nervous System

Corticosteroids should be used with caution in patients with seizure disorders.

Corticosteroids should be used with caution in patients with myasthenia gravis (See myopathy statement in **Musculoskeletal** section).

Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that corticosteroids affect the ultimate outcome or natural history of the disease. The studies do show that relatively

high doses of corticosteroids are necessary to demonstrate a significant effect. (See section **POSODOLOGY AND METHOD OF ADMINISTRATION**).

There have been reports of epidural lipomatosis in patients taking corticosteroids, typically with long-term use at high doses.

Ocular

Corticosteroids should be used cautiously in patient with ocular herpes simplex because of possible corneal perforation

Prolonged use of corticosteroids may produce posterior subcapsular cataracts and nuclear cataracts (particularly in children), exophthalmos, or increased intraocular pressure, which may result in glaucoma with possible damage to the optic nerves and may enhance the establishment of secondary ocular infections due to fungi or viruses.

Corticosteroid therapy has been associated with central serous chorioretinopathy, which may lead to retinal detachment.

Cardiac

Adverse effects of glucocorticoids on the cardiovascular system, such as dyslipidemia and hypertension, may predispose treated patients with existing cardiovascular risk factors to additional cardiovascular effects, if high doses and prolonged courses are used. Accordingly, corticosteroids should be employed judiciously in such patients and attention should be paid to risk modification and additional cardiac monitoring if needed. Low dose and alternate day therapy may reduce the incidence of complications in corticosteroid therapy.

Systemic corticosteroids should be used with caution, and only if strictly necessary, in cases of congestive heart failure.

Vascular

Thrombosis including venous thromboembolism has been reported to occur with corticosteroids. As a result, corticosteroids should be used with caution in patients who have or may be predisposed to thromboembolic disorders.

Corticosteroids should be used with caution in patients with hypertension.

Gastrointestinal

High doses of corticosteroids may produce acute pancreatitis.

There is no universal agreement on whether corticosteroids *per se* are responsible for peptic ulcer encountered during therapy; however, glucocorticoid therapy may mask the symptoms of peptic ulcer so that perforation or hemorrhage may occur without significant pain. Glucocorticoid therapy may mask peritonitis or other signs or symptoms associated with gastrointestinal disorders such as perforation, obstruction or pancreatitis. In combination with NSAIDs, the risk of developing gastrointestinal ulcers is increased.

Corticosteroids should be used with caution in non-specific ulcerative colitis if there is a probability of impending perforation, abscess or other pyogenic infection; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer.

Hepatobiliary

Hepatobiliary disorders have been reported which may be reversible after discontinuation of therapy. Therefore appropriate monitoring is required.

Musculoskeletal

An acute myopathy has been reported with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (e.g., myasthenia gravis), or in patients receiving concomitant therapy with anticholinergics, such as neuromuscular blocking drugs (e.g., pancuronium). This acute myopathy is generalized, may involve ocular and respiratory muscles, and may result in quadriparesis. Elevations of creatine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years.

Osteoporosis is a common but infrequently recognized adverse effects associated with a long-term use of large doses of glucocorticoid.

Renal and Urinary

Caution is required in patients with systemic sclerosis because an increased incidence of scleroderma renal crisis has been observed with corticosteroids, including methylprednisolone.

Corticosteroids should be used with caution in patients with renal insufficiency.

Investigations

Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt, and water retention, and increased excretion of potassium. These affects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.

Injury, Poisoning and Procedural Complications

Systemic corticosteroids are not indicated for, and therefore, should not be used to treat, traumatic brain injury; a multicenter study revealed an increased mortality at 2 weeks and 6 months after injury in patients administered methylprednisolone sodium succinate compared to placebo. A causal association with methylprednisolone sodium succinate treatment has not been established.

Other

Because complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.

The lowest possible dose of corticosteroid should be used to control the condition under treatment and when reduction in dosage is possible, the reduction should be gradual.

Aspirin and non-steroidal anti-inflammatory agents should be used cautiously in conjunction with corticosteroids.

Pheochromocytoma crisis, which can be fatal, has been reported after administration of systemic corticosteroids. Corticosteroids should only be administered to patients with suspected or identified pheochromocytoma after an appropriate risk/benefit evaluation.

Use in Children

Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed.

Growth may be suppressed in children receiving long-term daily, divided doses glucocorticoid therapy and use of such regimen should be restricted to the most urgent indication. Alternate day glucocorticoid therapy usually avoids or minimizes these side effects (See section **POSODOLOGY AND METHOD OF ADMINISTRATION**).

Infants and children on prolonged corticosteroid therapy are at special risk from raised intracranial pressure.

High doses of corticosteroids may produce pancreatitis in children.

Host defenses are impaired in patient receiving large doses of glucocorticoids and this effect increases susceptibility to fungus infection as well as bacterial and viral infections.

Fertility, Pregnancy and Lactation**Fertility**

Corticosteroids have been shown to impair fertility in animal studies (See section **Preclinical safety data**).

Pregnancy

Some animal studies have shown that corticosteroids, when administered to the mother at high doses, may cause fatal malformations.

Since adequate human reproductive studies have not been done with methylprednisolone, this medicinal product should be used during pregnancy only after a careful assessment of the benefit-risk ratio to the mother and fetus.

Some corticosteroids readily cross the placenta. One retrospective study found an increased incidence of low birth weights in infants born to mothers receiving corticosteroids. In humans, the risk of low birth weight appears to be dose related and may be minimized by administering lower corticosteroid doses. Infants born to mothers, who have received substantial doses of corticosteroids during pregnancy must be carefully observed and evaluated for signs of adrenal insufficiency, although neonatal adrenal insufficiency appears to be rare in infants who were exposed *in utero* to corticosteroids.

There are no known effects of corticosteroids on labor and delivery.

Lactation

Corticoids are excreted in breast milk and mothers taking the drug should not be breast feed. This medicinal product should be used during breast feeding only after a careful assessment of the benefit-risk ratio to the mother and infant.

Effects on ability to drive and use machines

The effect of corticosteroids on the ability to drive or use machinery has not been systematically evaluated.

Undesirable effects, such as dizziness, vertigo, visual disturbances and fatigue are possible after treatment with corticosteroids. If affected, patients should not drive or operate machinery.

PRECAUTIONS

Convulsions have been reported with concurrent use of methylprednisolone and cyclosporine. Since concurrent administration of these agents result in a mutual inhibition of metabolism, it is possible that convulsion and other adverse events associated with the individual use of either drug may be more apt to occur.

DRUG INTERACTIONS

Methylprednisolone is a cytochrome P450 enzyme (CYP) substrate and is mainly metabolized by the CYP3A4 enzyme. CYP3A4 is the dominant enzyme of the most abundant CYP subfamily in the liver of adult humans. It catalyzes 6 β -hydroxylation of steroids, the essential Phase I metabolic step for both endogenous and synthetic corticosteroids. Many other compounds are also substrates of CYP3A4, some of which (as well as other drugs) have been shown to alter glucocorticoid metabolism by induction (upregulation) or inhibition of the CYP3A4 enzyme.

CYP3A4 INHIBITORS - Drugs that inhibit CYP3A4 activity generally decrease hepatic clearance and increase the plasma concentration of CYP3A4 substrate medications, such as methylprednisolone. In the presence of a CYP3A4 inhibitor, the dose of methylprednisolone may need to be titrated to avoid steroid toxicity.

CYP3A4 INDUCERS - Drugs that induce CYP3A4 activity generally increase hepatic clearance, resulting in decreased plasma concentration of medications that are substrates for CYP3A4. Co-administration may require an increase in methylprednisolone dosage to achieve the desired result.

CYP3A4 SUBSTRATES - In the presence of another CYP3A4 substrate, the hepatic clearance of methylprednisolone may be affected, with corresponding dosage adjustments required. It is possible that adverse events associated with the use of either drug alone may be more likely to occur with co-administration.

NON-CYP3A4-MEDIATED EFFECTS – Other interactions and effects that occur with methylprednisolone are described in Table 1 below.

Table 1 provides a list and descriptions of the most common and/or clinically important drug interactions or effects with methylprednisolone.

Table 1. Important drug or substance interactions/effects with methylprednisolone

Drug Class or Type - DRUG or SUBSTANCE	Interaction/Effect
Antibacterial - ISONIAZID	CYP3A4 INHIBITOR. In addition, there is a potential effect of methylprednisolone to increase the acetylation rate and clearance of isoniazid.
Antibiotic, Antitubercular - RIFAMPIN - RIFABUTIN	CYP3A4 INDUCERS
Anticonvulsants - PHENOBARBITAL - PHENYTOIN - PRIMIDONE	CYP3A4 INDUCERS
Anticonvulsants - CARBAMAZEPINE	CYP3A4 INDUCER (and SUBSTRATE)
Macrolide Antibacterial - TROLEANDOMYCIN	CYP3A4 INHIBITOR
- GRAPEFRUIT JUICE	CYP3A4 INHIBITOR
Calcium Antagonist - MIBEFRADIL	CYP3A4 INHIBITOR
Histamine H2 receptor Antagonist - CIMETIDINE	CYP3A4 INHIBITOR
Anticholinesterases	Steroids may reduce the effects of anticholinesterases in myasthenia gravis.
Antidiabetics	Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.
Antiemetic - APREPITANT - FOSAPREPITANT	CYP3A4 INHIBITORS (and SUBSTRATES)
Antifungal - ITRACONAZOLE - KETOCONAZOLE	CYP3A4 INHIBITORS (and SUBSTRATES)
Calcium Channel Blocker - DILTIAZEM	CYP3A4 INHIBITORS (and SUBSTRATES)
Contraceptives (oral) - ETHINYLESTRADIOL/NORETHINDRONE	CYP3A4 INHIBITORS (and SUBSTRATES)
Immunosuppressant - CYCLOSPORINE	CYP3A4 INHIBITORS (and SUBSTRATES) 1) Mutual inhibition of metabolism occurs with concurrent use of cyclosporine and methylprednisolone, which may increase the plasma concentrations of either or both drugs. Therefore, it is possible that adverse events associated with the use of either drug alone may be more likely to occur upon co-administration. 2) Convulsions have been reported with concurrent use of methylprednisolone and cyclosporine.
Macrolide Antibacterial - CLARITHROMYCIN - ERYTHROMYCIN	CYP3A4 INHIBITORS (and SUBSTRATES)
Antivirals - HIV-PROTEASE INHIBITORS	CYP3A4 INHIBITORS (and SUBSTRATES) 1) Protease inhibitors, such as indinavir and ritonavir, may increase plasma concentrations of corticosteroids. 2) Corticosteroids may induce the metabolism of HIV-protease inhibitors resulting in reduced plasma concentrations.

Drug Class or Type - DRUG or SUBSTANCE	Interaction/Effect
Aromatase inhibitors - AMINOGLUTETHIMIDE	Aminoglutethimide-induced adrenal suppression may exacerbate endocrine changes caused by prolonged glucocorticoid treatment.
Immunosuppressant - CYCLOPHOSPHAMIDE - TACROLIMUS	CYP3A4 SUBSTRATES
NSAIDs (non-steroidal anti-inflammatory drugs) - high-dose ASPIRIN (acetylsalicylic acid)	NON-CYP3A4-MEDIATED EFFECTS 1) There may be increased incidence of gastrointestinal bleeding and ulceration when corticosteroids are given with NSAIDs. 2) Methylprednisolone may increase the clearance of high-dose aspirin, which can lead to decreased salicylate serum levels. Discontinuation of methylprednisolone treatment can lead to raised salicylate serum levels, which could lead to an increased risk of salicylate toxicity.
Anticholinergics - NEUROMUSCULAR BLOCKERS	Corticosteroids may influence the effect of anticholinergics. 1) An acute myopathy has been reported with the concomitant use of high doses of corticosteroids and anticholinergics, such as neuromuscular blocking drugs. (See section WARNINGS , Musculoskeletal, for additional information) 2) Antagonism of the neuromuscular blocking effects of pancuronium and vecuronium has been reported in patients taking corticosteroids. This interaction may be expected with all competitive neuromuscular blockers.
Anticoagulants (oral)	The efficacy of coumarin anticoagulants may be enhanced by concurrent corticosteroid therapy and close monitoring of the INR or prothrombin time is required to avoid spontaneous bleeding.
Potassium-depleting agents	When corticosteroids are administered concomitantly with potassium-depleting agents (i.e., diuretics), patients should be observed closely for development of hypokalemia. There is also an increased risk of hypokalemia with concurrent use of corticosteroids with amphotericin B, xanthenes, or beta2 agonists.

ADVERSE REACTIONS

ADRs by SOC and CIOMS frequency category listed in order of decreasing medical seriousness within each frequency category and SOC

System Organ Class	Very Common ≥1/10	Common ≥1/100 to <1/10	Uncommon ≥1/1,000 to <1/100	Rare ≥1/10,000 to <1/1,000	Very Rare <1/10,000	Frequency Not Known (cannot be estimated from the available data)
Infections and infestations						Opportunistic infection, Infection, Peritonitis [†]
Blood and lymphatic system disorders						Leukocytosis
Immune system disorders						Drug hypersensitivity, Anaphylactic reaction, Anaphylactoid reaction

System Organ Class	Very Common ≥1/10	Common ≥1/100 to <1/10	Uncommon ≥1/1,000 to <1/100	Rare ≥1/10,000 to <1/1,000	Very Rare <1/10,000	Frequency Not Known (cannot be estimated from the available data)
Endocrine disorders						Cushingoid, Hypopituitarism, Steroid withdrawal syndrome
Metabolism and nutrition disorders						Metabolic acidosis, Sodium retention, Fluid retention, Alkalosis hypokalaemic, Dyslipidaemia, Glucose tolerance impaired, Increased insulin requirement (or oral hypoglycemic agents in diabetics), Lipomatosis, Increased appetite (which may result in Weight increased)
Psychiatric disorders						Affective disorder (including Depressed mood, Euphoric mood, Affect lability, Drug dependence, Suicidal ideation), Psychotic disorder (including Mania, Delusion, Hallucination, and Schizophrenia), Psychotic behaviour, Mental disorder, Personality change, Confusional state, Anxiety, Mood swings, Abnormal behaviour, Insomnia, Irritability
Nervous system disorders						Epidural lipomatosis, Intracranial pressure increased (with Papilloedema [Benign intracranial hypertension]), Seizure, Amnesia, Cognitive disorder, Dizziness, Headache
Eye disorders						Chorioretinopathy, Cataract, Glaucoma, Exophthalmos
Ear and labyrinth disorders						Vertigo
Cardiac disorders						Cardiac failure congestive (in susceptible patients)
Vascular disorders						Thrombosis, Hypertension, Hypotension
Respiratory, thoracic and mediastinal disorders						Pulmonary embolism, Hiccups
Gastrointestinal disorders						Peptic ulcer (with possible Peptic ulcer perforation and Peptic ulcer haemorrhage), Intestinal perforation, Gastric haemorrhage, Pancreatitis, Oesophagitis ulcerative, Oesophagitis, Abdominal distension, Abdominal pain, Diarrhoea, Dyspepsia, Nausea
Skin and						Angioedema, Hirsutism,

System Organ Class	Very Common ≥1/10	Common ≥1/100 to <1/10	Uncommon ≥1/1,000 to <1/100	Rare ≥1/10,000 to <1/1,000	Very Rare <1/10,000	Frequency Not Known (cannot be estimated from the available data)
subcutaneous tissue disorders						Petechiae, Ecchymosis, Skin atrophy, Erythema, Hyperhidrosis, Skin striae, Rash, Pruritus, Urticaria, Acne
Musculoskeletal and connective tissue disorders						Muscular weakness, Myalgia, Myopathy, Muscle atrophy, Osteoporosis, Osteonecrosis, Pathological fracture, Neuropathic arthropathy, Arthralgia, Growth retardation
Reproductive system and breast disorders						Menstruation irregular
General disorders and administration site conditions						Impaired healing, Oedema peripheral, Fatigue, Malaise
Investigations						Intraocular pressure increased, Carbohydrate tolerance decreased, Blood potassium decreased, Urine calcium increased, Alanine aminotransferase increased, Aspartate aminotransferase increased, Blood alkaline phosphatase increased, Blood urea increased, Suppression of reactions to skin tests*
Injury, poisoning and procedural complications						Spinal compression fracture, Tendon rupture

* Not a MedDRA PT

† Peritonitis may be the primary presenting sign or symptom of a gastrointestinal disorder such as perforation, obstruction or pancreatitis (See section **WARNINGS**).

Overdose

There is no clinical syndrome of acute overdosage with corticosteroids.

Reports of acute toxicity and/or death following overdosage of corticosteroids are rare. In the event of overdosage, no specific antidote is available; treatment is supportive and symptomatic.

Methylprednisolone is dialyzable.

POSODOLOGY AND METHOD OF ADMINISTRATION

The initial dosage of MEDROL® Tablets may vary from 4 mg to 48 mg as methylprednisolone per day depending on the specific disease entity being treated. In situations less severity, lower doses will generally suffice while in selected patients higher initial doses may be required. Clinical situation in which high dose therapy may be indicated include multiple sclerosis (160

mg/day for a week followed by 64 mg every other day for 1 month have been shown to be effective). If after a reasonable period of time there is a lack of satisfactory clinical response, MEDROL® should be discontinued and the patient transferred to other appropriate therapy. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.

After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrement at appropriate time interval until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situation which may make dosage adjustment necessary are changes in clinical status secondary to remission or exacerbation in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situation not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of MEDROL® for a period of time consistent with the patient's condition.

IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT.

Alternate Day Therapy (ADT): Alternate day therapy is a corticosteroid dosing regimen in which twice the usual daily dose of corticosteroid is administered every other morning. The purpose of this mode of therapy is to provide a patient requiring long-term pharmacologic dose treatment with the beneficial effect of corticosteroid, including pituitary-adrenal suppression, the Cushingoid state, corticoid withdrawal symptoms, and growth suppression in children.

Elderly patient: Treatment of elderly patients, particularly if long-term, should be planned bearing in mind the more serious consequences of the common side effects of corticosteroid in old age, particularly osteoporosis, diabetes, hypertension, susceptibility to infection and thinning of skin.

Children: In general dosage for children should be based upon clinical response and is at the discretion of the clinician. Treatment should be limited to the minimum dosage for the shortest period of time. If possible, treatment should be administered as a single dose on alternate days.

HOW SUPPLIED

MEDROL® Tablet 4 mg: Box of 10 blisters @ 10 tablets, Reg. No. DK10554200510A1

MEDROL® Tablet 16 mg: Box of 3 blisters @ 10 tablets, Reg. No. DK10554200510B1

Store below 25°C (MEDROL® 16 mg)

Store below 30°C (MEDROL® 4 mg)

HARUS DENGAN RESEP DOKTER

Manufactured by:

Pfizer Italia S.r.l., Ascoli, Italy

Imported by:

PT. Pfizer Indonesia
Jakarta, Indonesia

Nama Generik: Metilprednisolon tablet
Nama Dagang: MEDROL®
Tanggal Berlaku CDS: 26 Juni 2019
Menggantikan: NA
Disetujui oleh BPOM:

Leaflet kemasan: Informasi bagi pengguna

MEDROL® 4 mg Tablet MEDROL® 16 mg Tablet Metilprednisolon

Baca semua bagian leaflet ini dengan cermat sebelum mulai menggunakan obat ini karena berisi informasi penting untuk Anda.

- Simpan leaflet ini. Anda mungkin perlu membacanya kembali.
- Jika Anda memiliki pertanyaan lebih lanjut, tanyakan kepada dokter, apoteker, atau perawat Anda.
- Obat ini telah diresepkan hanya untuk Anda. Jangan berikan kepada orang lain. Obat ini dapat membahayakan mereka, sekali pun tanda-tanda penyakit mereka sama dengan Anda.
- Jika Anda mengalami efek samping apa pun, berkonsultasilah dengan dokter, apoteker, atau perawat Anda. Ini termasuk segala kemungkinan efek samping yang tidak tercantum di dalam leaflet ini. Lihat bagian 8.

Apa isi leaflet ini?

1. Nama produk
2. Keterangan produk
3. Apa kandungan obat ini?
4. Kekuatan obat
5. Apa kegunaan obat ini?
6. Berapa banyak dan seberapa sering obat ini boleh digunakan? Apa yang harus dilakukan bila lupa minum obat ini?
7. Pada keadaan apa Anda tidak diperbolehkan menggunakan obat ini?
8. Efek yang tidak diinginkan
9. Apa saja obat lain atau makanan yang harus dihindari selama menggunakan obat ini?
10. Apa yang harus dilakukan jika ada dosis terlewat?
11. Bagaimana cara menyimpan obat ini?
12. Tanda-tanda dan gejala-gejala kelebihan dosis
13. Apa yang harus dilakukan jika Anda menggunakan lebih dari dosis yang dianjurkan?
14. Apa saja yang perlu diperhatikan saat menggunakan obat ini?
15. Kapan sebaiknya Anda berkonsultasi dengan dokter?
16. Nama produsen/importir/Pemegang Hak Pemasaran
17. Tanggal revisi

1. Nama produk

MEDROL® 4 mg Tablet
MEDROL® 16 mg Tablet

2. Keterangan produk

Obat ini mengandung metilprednisolon, yang termasuk dalam golongan obat-obatan yang disebut steroid. Nama lengkapnya adalah kortikosteroid. Kortikosteroid diproduksi secara alami dalam tubuh Anda dan bersifat penting bagi banyak fungsi tubuh.

MEDROL® 4 mg: Tablet putih, setengah oval, elips, dengan gravir "Medrol 4" di satu sisi dan dua torehan garis di sisi lainnya.

MEDROL® 16 mg: Tablet putih elips, cembung, dengan gravir "Medrol 16" di satu sisi dan torehan tanda silang di sisi lainnya.

3. Apa kandungan obat ini?

Zat aktifnya adalah metilprednisolon. Setiap tablet mengandung 4 atau 16 mg metilprednisolon.

Nama Generik: Metilprednisolon tablet
Nama Dagang: MEDROL®
Tanggal Berlaku CDS: 26 Juni 2019
Menggantikan: NA
Disetujui oleh BPOM:

4. Kekuatan obat

4 mg; 16 mg.

5. Apa kegunaan obat ini?

Dokter Anda telah meresepkan MEDROL® untuk mengobati satu atau beberapa kondisi berikut ini:

- penyakit kulit
- reaksi alergi
- peradangan mata
- penyakit pernapasan dan infeksi pernapasan tertentu
- penyakit usus (saluran cerna)
- sklerosis multipel
- kelainan rematik
- penyakit darah
- pengobatan untuk kondisi kelenjar tertentu.

Dokter Anda mungkin meresepkan MEDROL® karena alasan lain.

Anda harus berkonsultasi dengan dokter jika Anda tidak yakin mengapa obat ini diresepkan untuk Anda, jika Anda tidak merasa membaik, atau jika Anda merasa bertambah parah.

6. Berapa banyak dan seberapa sering obat ini boleh digunakan? Apa yang harus dilakukan bila lupa minum obat ini?

Selalu minum obat ini dengan tepat sesuai anjuran dokter atau apoteker Anda. Tanyakan kepada dokter atau apoteker jika Anda merasa tidak yakin.

Orang Dewasa

Dosis normal harian adalah antara 4 mg hingga 48 mg per hari, bergantung pada kondisi Anda serta tingkat keparahannya. Dokter akan meresepkan dosis serendah mungkin.

Dokter Anda dapat meminta Anda untuk minum dosis harian sekaligus, membagi dosis harian Anda beberapa kali dalam sehari, atau meminumnya dalam sehari sekali.

Telan tablet **secara utuh** dengan segelas air. Garis pada tablet tidak ditujukan untuk mematahkan tablet.

Jangan memakan buah jeruk bali atau minum jus jeruk bali selama minum MEDROL®.

Dokter mungkin akan meresepkan dosis yang lebih tinggi di awal pengobatan untuk mengendalikan kondisi Anda.

Jika dokter merasa puas dengan kondisi Anda yang membaik maka dosis Anda akan dikurangi secara bertahap.

Lansia:

Anda mungkin perlu lebih sering berkunjung ke dokter agar dapat memeriksa kemajuan Anda dengan minum obat ini.

Pasien anak-anak dan remaja:

Kortikosteroid dapat memengaruhi pertumbuhan anak-anak, sehingga dokter Anda akan meresepkan dosis paling rendah yang efektif bagi anak Anda. Dokter dapat meminta Anda untuk memberikan obat ini kepada anak Anda setiap hari.

Nama Generik: Metilprednisolon tablet
Nama Dagang: MEDROL®
Tanggal Berlaku CDS: 26 Juni 2019
Menggantikan: NA
Disetujui oleh BPOM:

Jika Anda meminum MEDROL® melebihi dosis yang seharusnya

Penting kiranya agar Anda tidak meminum tablet melebihi dosis yang diresepkan. Jika Anda tanpa sengaja meminum tablet terlalu banyak, segeralah meminta penanganan medis.

Jika Anda lupa untuk meminum MEDROL®

Tunggu dan minumlah dosis berikutnya secara normal. Jangan meminum dosis obat untuk menggantikan dosis yang terlupa tetapi beri tahu dokter atau apoteker Anda apa yang telah terjadi.

Menghentikan/menurunkan dosis MEDROL® Anda

Dokter akan memutuskan kapan waktu yang tepat untuk menghentikan dosis Anda.

Anda tidak boleh berhenti meminum MEDROL® secara mendadak.

Anda harus berhenti meminum MEDROL® secara perlahan untuk menghindari **gejala putus obat**. Gejala-gejalanya meliputi gatal-gatal pada kulit, demam, nyeri otot dan sendi, hidung berair, mata lengket, hilang selera makan, mual, muntah, sakit kepala, merasa lelah, kulit mengelupas, dan penurunan berat badan.

Jika gejala-gejala Anda muncul kembali atau bertambah parah setelah dosis MEDROL® Anda diturunkan, segera beri tahu dokter Anda.

Gangguan mental selama meminum MEDROL®

Gangguan kesehatan mental dapat terjadi selama meminum steroid seperti MEDROL® (lihat bagian 4).

- Penyakit ini dapat bersifat serius.
- Biasanya dimulai dalam beberapa hari atau minggu setelah mulai meminum obat.
- Kecenderungan untuk terjadi akan lebih besar untuk dosis tinggi.
- Sebagian besar masalah ini akan mereda jika dosis diturunkan atau obat dihentikan. Namun demikian, jika masalah timbul maka pengobatan mungkin perlu diberikan.

Konsultasikan dengan dokter jika Anda (atau seseorang yang menggunakan obat ini) menunjukkan tanda-tanda gangguan mental. Hal ini penting khususnya jika Anda merasa depresi, atau mungkin memiliki pikiran untuk bunuh diri. Dalam beberapa kasus, gangguan mental terjadi jika dosis diturunkan atau dihentikan.

Jika Anda memiliki pertanyaan lebih lanjut seputar penggunaan obat ini, tanyakan kepada dokter atau apoteker Anda.

7. Pada keadaan apa Anda tidak diperbolehkan menggunakan obat ini?

Jangan meminum MEDROL®:

- Jika Anda merasa pernah mengalami **reaksi alergi** (reaksi anafilaksis), atau jenis reaksi lainnya setelah meminum MEDROL® atau bahan lainnya yang terkandung dalam obat ini. Reaksi alergi dapat menyebabkan ruam kulit atau kulit memerah, wajah atau bibir membengkak, atau sesak napas.
- Jika Anda baru-baru ini telah, atau akan menerima **vaksinasi**.

Kehamilan dan menyusui

Jika Anda hamil, menduga bahwa diri Anda hamil, atau sedang merencanakan kehamilan, mintalah saran dari dokter atau apoteker Anda sebelum menggunakan obat ini, karena dapat memperlambat

pertumbuhan janin. Terdapat risiko berat bayi lahir rendah; risiko ini dapat diminimalkan dengan meminum dosis efektif terendah kortikosteroid.

Jika Anda sedang menyusui, mintalah saran kepada dokter atau apoteker Anda, karena sejumlah kecil obat kortikosteroid dapat masuk ke dalam ASI.

Mengemudi dan menggunakan mesin

Efek yang tidak diinginkan, seperti pusing, vertigo, gangguan penglihatan, dan kelelahan mungkin terjadi setelah pengobatan dengan kortikosteroid. Jika Anda mengalami kondisi tersebut di atas, jangan mengemudi atau mengoperasikan mesin.

MEDROL® mengandung laktosa dan sukrosa

Jika Anda telah diberi tahu oleh dokter bahwa Anda mempunyai intoleransi terhadap jenis gula tertentu, sampaikan kepada dokter Anda sebelum meminum obat ini.

Obat ini mengandung laktosa yang dihasilkan dari susu sapi. Kehati-hatian perlu diterapkan pada pasien yang diketahui atau diduga mengidap hipersensitivitas terhadap susu sapi atau komponennya atau produk susu lainnya karena bisa jadi mengandung kadar runtu bahan susu.

8. Efek yang tidak diinginkan

Seperti semua obat-obatan yang ada, obat ini bisa menimbulkan efek samping, meskipun tidak semua orang mengalaminya. Dokter Anda akan memberikan obat ini untuk suatu kondisi yang jika tidak diobati dengan benar dapat bertambah serius.

Efek samping ini dapat terjadi dengan frekuensi tertentu yang dinyatakan sebagai berikut:

- *umum*: dapat dialami hingga 1 di antara 10 orang.
- *jarang*: dapat dialami hingga 1 di antara 1000 orang.
- *tidak diketahui*: frekuensinya tidak dapat diperkirakan dari data yang tersedia.

Dalam kondisi medis tertentu, obat-obatan seperti MEDROL® (steroid) tidak boleh dihentikan secara tiba-tiba. Jika Anda mengalami gejala mana pun berikut ini, SEGERA dapatkan penanganan medis. Dokter selanjutnya akan memutuskan apakah Anda harus tetap meminum obat ini:

tidak diketahui

- **Tukak yang pecah atau berdarah**, gejala-gejalanya meliputi sakit perut (khususnya jika tampak menyebar hingga ke punggung Anda), perdarahan saat BAB, feses berwarna hitam atau dengan bercak darah, dan/atau muntah darah.
- **Infeksi**. Obat ini dapat menyamarkan atau mengubah tanda-tanda dan gejala-gejala infeksi, atau menurunkan resistansi terhadap infeksi, sehingga sulit untuk didiagnosis pada tahap awal. Gejala-gejalanya meliputi peningkatan suhu dan tidak enak badan. MEDROL® juga dapat membuat Anda lebih cenderung mengalami infeksi berat.
- **Reaksi alergi**, seperti ruam kulit, pembengkakan wajah, atau mengi dan kesulitan bernapas. Jenis efek samping ini tergolong jarang, tetapi dapat berakibat serius.
- **Pankreatitis**, sakit perut yang menyebar hingga ke punggung Anda, kemungkinan disertai dengan muntah, syok, dan hilang kesadaran.
- **Emboli paru** (bekuan darah dalam paru), gejalanya meliputi nyeri dada yang tajam dan muncul tiba-tiba, sesak napas, dan batuk darah.
- **Peningkatan tekanan dalam tengkorak** anak-anak (pseudotumour cerebri) dengan gejala-gejala meliputi muntah, kekurangan energi, dan mengantuk. Efek samping ini biasanya terjadi setelah pengobatan dihentikan.

- **Tromboflebitis** (bekuan darah atau trombosis di pembuluh vena kaki), gejalanya meliputi pembuluh vena yang membengkak dan terasa sakit, memerah, dan nyeri tekan.

Jika Anda mengalami salah satu efek samping berikut, atau merasa ada efek yang tidak wajar yang tidak disebutkan dalam leaflet ini, segera beri tahu dokter Anda.

Darah, jantung, dan sirkulasi

tidak diketahui

- Tekanan darah tinggi, gejala-gejalanya meliputi sakit kepala atau merasa tidak enak badan.
- Gangguan pemompaan jantung (gagal jantung), gejalanya meliputi pergelangan kaki yang membengkak, kesulitan bernapas dan palpitasi (kesadaran denyut jantung) atau denyut jantung tidak teratur, denyut nadi yang tidak teratur, atau sangat cepat, atau lambat.
- Peningkatan jumlah sel darah putih (leukositosis).
- Tekanan darah rendah.

Kandungan air dan garam dalam tubuh

tidak diketahui

- Pembengkakan dan tekanan darah tinggi yang disebabkan oleh peningkatan kadar air dan garam dalam tubuh.
- Kram dan spasme dikarenakan hilangnya kalium dari tubuh Anda. Dalam kasus yang jarang terjadi, hal ini dapat menyebabkan gagal jantung kongestif (saat jantung tidak dapat memompa dengan baik).
- Peningkatan kadar urea darah.

Sistem pencernaan

tidak diketahui

- Mual atau muntah.
- Tukak, peradangan (nyeri, bengkak, kemerahan, dan panas), atau sariawan di dalam esofagus (saluran yang menghubungkan mulut dengan lambung Anda), yang dapat menyebabkan ketidaknyamanan saat menelan.
- Peradangan selaput tipis (peritoneum) di sekitar usus dan lambung.
- Gangguan pencernaan.
- Perut kembung.
- Nyeri abdomen.
- Diare.
- Cegukan terus-menerus, khususnya jika meminum dosis tinggi.

Mata

tidak diketahui

- Kerusakan saraf optik atau katarak (diindikasikan dengan gangguan penglihatan).
- Glaukoma (meningkatnya tekanan di dalam mata, sehingga menyebabkan nyeri di dalam mata dan sakit kepala).
- Pembengkakan saraf optik (papiledema, yang diindikasikan dengan gangguan penglihatan).
- Bertambah parahnya infeksi mata yang disebabkan oleh virus atau jamur.
- Menonjolnya bola mata (eksoftalmus).

Gangguan hepatobilier

tidak diketahui

- Peningkatan enzim hati (misalnya ALT atau AST).

Hormon dan sistem metabolik

tidak diketahui

Nama Generik: Metilprednisolon tablet
Nama Dagang: MEDROL®
Tanggal Berlaku CDS: 26 Juni 2019
Menggantikan: NA
Disetujui oleh BPOM:

- Melambatnya pertumbuhan normal pada bayi, anak-anak, dan remaja yang dapat bersifat permanen.
- Wajah berbentuk bulat atau bulan (sindrom Cushing).
- Haid tidak teratur atau tidak haid sama sekali pada perempuan.
- Bertambah lebatnya rambut pada tubuh dan wajah perempuan (hirsutisme).
- Meningkatnya selera makan dan kenaikan berat badan.
- Kadar lipid dalam darah abnormal (misalnya kolesterol dan/atau lemak). Diabetes atau bertambah parahnya diabetes yang sudah diderita.
- Terapi yang berlangsung lama dapat menyebabkan penurunan kadar beberapa jenis hormon yang pada gilirannya dapat menyebabkan tekanan darah rendah dan pusing. Efek ini dapat berlangsung terus selama beberapa bulan.
- Kadar bahan kimia tertentu (enzim) yang disebut alanin transaminase, aspartat transaminase, dan alkalik fosfatase yang membantu tubuh untuk mencerna obat dan zat lain dalam tubuh Anda dapat mengalami peningkatan setelah menjalani pengobatan dengan kortikosteroid. Perubahan tersebut biasanya berskala kecil dan kadar enzim akan kembali normal setelah obat dibersihkan secara alami dari sistem peredaran darah Anda. Anda tidak akan merasakan gejala apa pun saat hal ini terjadi, tetapi akan muncul setelah Anda menjalani tes darah.
- Akumulasi jaringan lemak pada bagian tubuh yang terlokalisasi, dengan manifestasi yang berbeda, misalnya sakit punggung atau rasa lemah (dikarenakan epidural lipomatosis).

Sistem imun

tidak diketahui

- Peningkatan kerentanan terhadap infeksi yang dapat menyamarkan atau mengubah reaksi normal terhadap tes kulit, seperti tes untuk tuberkulosis (TB).

Otot dan tulang

tidak diketahui

- Kelemahan atau penyusutan otot.
- Tulang rapuh (tulang yang mudah retak).
- Tulang patah atau fraktur.
- Penurunan kepadatan tulang akibat sirkulasi darah yang buruk, hal ini menyebabkan nyeri di panggul.
- Nyeri sendi atau gangguan sendi.
- Tendon otot sobek yang menyebabkan nyeri dan/atau pembengkakan.
- Nyeri otot, kram, atau spasme.

Sistem saraf

Steroid termasuk metilprednisolon dapat menyebabkan gangguan kesehatan mental serius.

tidak diketahui

- Merasa depresi, termasuk munculnya pikiran untuk bunuh diri.
- Merasa euforia (mania) atau suasana hati yang naik turun.
- Merasa cemas, mengalami gangguan tidur, kesulitan berpikir, atau merasa bingung dan kehilangan memori.
- Merasakan, melihat, atau mendengar hal-hal yang sesungguhnya tidak ada. Memiliki pemikiran yang aneh dan menakutkan, mengubah cara Anda bertindak, atau merasa kesepian.
- Mudah marah.
- Kejang.
- Pusing, merasa pusing, atau 'berputar'.
- Sakit kepala.

Kulit

tidak diketahui

Nama Generik: Metilprednisolon tablet
Nama Dagang: MEDROL®
Tanggal Berlaku CDS: 26 Juni 2019
Menggantikan: NA
Disetujui oleh BPOM:

- Jerawat.
- Penyembuhan luka yang lambat.
- Kulit menipis.
- Gurat peregangan.
- Lebam.
- Berkeringat.
- Kulit gatal.
- Ruam atau kulit kemerahan.
- Kaligata (pembengkakan yang merah dan gatal).
- Bintik bulat berukuran kecil dan berwarna merah, coklat, atau ungu.

Kelainan vaskular

tidak diketahui

- Peningkatan bekuan darah

Efek samping lainnya

tidak diketahui

- Merasa tidak enak badan.
- Merasa lelah.
- Akumulasi cairan yang menyebabkan pembengkakan pada tubuh, khususnya anggota gerak bagian bawah.
- Supresi reaksi terhadap tes kulit.

Penting bagi Anda yang akan menjalani tes darah untuk memberi tahu dokter atau perawat bahwa Anda sedang menjalani pengobatan dengan MEDROL®.

Jika Anda mengalami efek samping apa pun yang tertera di atas, segera beri tahu dokter Anda.

Melaporkan efek samping

Jika Anda mengalami efek samping, konsultasikan dengan dokter atau apoteker Anda. Ini termasuk segala kemungkinan efek samping yang tidak tercantum di dalam leaflet ini. Dengan melaporkan efek samping, Anda bisa membantu memberikan informasi lebih lanjut mengenai keamanan obat ini.

9. Apa saja obat lain atau makanan yang harus dihindari selama menggunakan obat ini?

Beri tahu dokter atau apoteker jika Anda meminum, baru saja meminum, atau mungkin meminum obat-obatan lain, termasuk obat-obatan yang diperoleh tanpa resep. Hal ini dapat berbahaya atau memengaruhi cara kerja MEDROL® atau obat lainnya:

- **Aminoglutetimid** atau **Siklofosfamid** – digunakan untuk mengobati kanker.
- **Antikoagulan** - digunakan untuk ‘mengencerkan’ darah seperti asenokumarol, fenindion, dan warfarin.
- **Antikolinesterase** - digunakan untuk mengobati miastenia gravis (kondisi otot) seperti distigmin dan neostigmin.
- **Antibakteri** (seperti isoniazid, eritromisin, klaritromisin, dan troleandomisin).
- **Antidiabetik** – obat-obatan yang digunakan untuk mengobati kadar gula darah tinggi.
- **Aprepitant** atau **fosaprepitan** – digunakan untuk mengobati mual dan muntah.
- **Aspirin** dan obat-obatan antiinflamasi nonsteroid (disebut juga **OAINS**) seperti ibuprofen yang digunakan untuk mengobati nyeri ringan hingga sedang.
- **Barbiturat**, **fenitoin** dan **primidon** – digunakan untuk mengobati epilepsi.
- **Simetidin** - digunakan untuk mengobati nyeri ulu hati dan nyeri terbakar di dada.

Nama Generik: Metilprednisolon tablet
Nama Dagang: MEDROL®
Tanggal Berlaku CDS: 26 Juni 2019
Menggantikan: NA
Disetujui oleh BPOM:

- **Diltiazem** atau **mibefradil** – digunakan untuk gangguan jantung atau tekanan darah tinggi.
- **Antivirus** (seperti ritonavir, indinavir) digunakan untuk mengobati infeksi HIV.
- **Ketokonazol** atau **itraconazol** – digunakan untuk mengobati infeksi jamur.
- **Pankuronium** atau **vecuronium** – atau obat-obatan lain yang disebut agen pemblokir neuromuskular, yang digunakan dalam beberapa prosedur pembedahan.
- **Agen penurun kalium** – seperti **diuretik** (kadang-kadang disebut tablet air), **amfoterisin B**, **xanthene**, atau **agonis beta2** (misalnya obat-obatan yang digunakan untuk mengobati asma).
- **Rifampisin** dan **rifabutin** – antibiotik yang digunakan untuk mengobati tuberkulosis (TB).
- **Takrolimus** – digunakan setelah transplantasi organ untuk mencegah penolakan organ.
- **Vaksin** - beri tahu dokter Anda atau perawat jika Anda baru saja atau akan menjalani vaksinasi. Anda **tidak boleh** menerima vaksin 'hidup' saat menggunakan obat ini. Vaksin lain mungkin menjadi kurang efektif.

Jika Anda menggunakan pengobatan jangka panjang

Jika Anda sedang menjalani pengobatan untuk diabetes, tekanan darah tinggi, atau retensi air (edema), beri tahu dokter Anda karena ia mungkin perlu menyesuaikan dosis obat yang digunakan untuk mengobati kondisi ini.

Sebelum Anda menjalani operasi beri tahu dokter, dokter gigi, atau dokter anestesi Anda bahwa Anda sedang minum MEDROL®.

Jika Anda perlu menjalani tes yang dilakukan oleh dokter atau di rumah sakit maka penting bagi Anda untuk memberi tahu dokter atau perawat Anda bahwa Anda sedang minum MEDROL®. Obat ini dapat memengaruhi hasil sejumlah tes.

10. Apa yang harus dilakukan jika ada dosis terlewat?

Tunggu dan minumlah dosis berikutnya secara normal. Jangan minum dosis obat untuk menggantikan dosis yang terlupa tetapi beri tahu dokter atau apoteker Anda apa yang telah terjadi.

11. Bagaimana cara menyimpan obat ini?

Jauhkan obat ini dari pandangan dan jangkauan anak-anak.

Jangan gunakan obat ini jika sudah melewati tanggal kedaluwarsanya. Tanggal kedaluwarsa mengacu pada hari terakhir dari bulan yang tertera.

Simpan pada suhu di bawah 25 °C (MEDROL® 16 mg/tablet)

Simpan pada suhu di bawah 30°C (MEDROL® 4 mg/tablet)

Jangan buang obat melalui saluran pembuangan air atau bersama sampah rumah tangga. Tanyakan kepada apoteker cara membuang obat yang sudah tidak digunakan lagi. Langkah-langkah ini akan membantu melindungi lingkungan.

12. Tanda-tanda dan gejala-gejala kelebihan dosis

Tidak ada gejala klinis untuk kelebihan dosis akut terkait kortikosteroid. Laporan adanya toksisitas akut dan/atau kematian setelah kelebihan dosis kortikosteroid tergolong jarang.

13. Apa yang harus dilakukan jika Anda menggunakan lebih dari dosis yang dianjurkan?

Penting kiranya bagi Anda untuk tidak minum tablet melebihi dosis yang diresepkan. Segera hubungi dokter atau apoteker Anda jika Anda minum obat ini melebihi dosis yang diresepkan oleh dokter Anda.

14. Apa saja yang perlu diperhatikan saat menggunakan obat ini?

Nama Generik: Metilprednisolon tablet
Nama Dagang: MEDROL®
Tanggal Berlaku CDS: 26 Juni 2019
Menggantikan: NA
Disetujui oleh BPOM:

Peringatan dan tindakan pencegahan

Konsultasikan dengan dokter atau apoteker Anda sebelum meminum obat ini jika Anda menderita salah satu kondisi berikut ini.

Dokter Anda mungkin perlu memantau pengobatan Anda dengan lebih saksama, mengubah dosis Anda, atau memberi Anda obat lainnya.

- **Cacar air, campak, atau herpes.** Jika Anda merasa telah mengalami kontak dengan seseorang yang menderita cacar air, campak, atau herpes, dan Anda belum pernah terkena penyakit-penyakit tersebut, atau jika Anda tidak yakin apakah Anda pernah terkena sebelumnya.
- **Diabetes** (atau jika ada riwayat diabetes dalam keluarga).
- **Kejang.**
- **Glaukoma** (peningkatan tekanan di dalam mata) atau jika terdapat riwayat glaukoma di dalam keluarga, atau jika Anda menderita **katarak**.
- Infeksi mata akibat **virus** (misalnya herpes) atau **jamur**.
- Anda baru-baru ini mengalami **serangan jantung**.
- **Gangguan jantung**, termasuk gagal jantung.
- **Hipertensi** (tekanan darah tinggi).
- **Hipotiroidisme** (kelainan akibat kekurangan hormone tiroid).
- **Pankreatitis** (peradangan pankreas yang menyebabkan nyeri berat pada abdomen dan punggung).
- **Peritonitis** (peradangan selaput tipis (peritoneum) di sekitar usus dan lambung).
- Penyakit **ginjal** atau **hati**.
- **Skleroderma** (disebut juga sebagai sklerosis sistemik, suatu gangguan autoimun), karena risiko komplikasi serius yang disebut krisis ginjal skleroderma dapat meningkat. Tanda-tanda krisis ginjal skleroderma di antaranya peningkatan tekanan darah dan penurunan produksi urine.
- **Gangguan otot** (nyeri atau lemah) telah terjadi saat meminum obat-obatan steroid seperti MEDROL® di waktu lalu.
- **Miastenia gravis** (suatu kondisi yang menyebabkan otot terasa lelah dan lemah).
- **Osteoporosis** (tulang rapuh).
- **Feokromositoma** (sejenis tumor langka pada jaringan kelenjar adrenal. Kelenjar adrenal terdapat di atas ginjal).
- **Abses kulit.**
- **Tukak lambung** atau gangguan lambung atau usus lainnya yang serius.
- **Tuberkulosis (TB)** atau jika Anda pernah mengidap tuberkulosis di waktu lalu.
- **Penyakit Cushing** (kondisi yang disebabkan oleh kelebihan hormon kortisol dalam tubuh Anda).
- **Cedera otak** dikarenakan trauma (cedera).
- **Stres yang tidak lazim.**

15. Kapan sebaiknya Anda berkonsultasi dengan dokter?

Jika Anda memiliki pertanyaan lebih lanjut atau Anda mengalami situasi yang sama seperti yang tercantum dalam leaflet ini, konsultasikan dengan dokter, apoteker, atau perawat Anda.

16. Nama produsen/importir/Pemegang Hak Pemasaran

MEDROL® 4 mg Tablet: Dus berisi 10 blister @ 10 tablet, No. Reg. DK10554200510A1

MEDROL® 16 mg Tablet: Dus berisi 3 blister @ 10 tablet, No. Reg. DK10554200510B1

HARUS DENGAN RESEP DOKTER

Nama Generik: Metilprednisolon tablet
Nama Dagang: MEDROL®
Tanggal Berlaku CDS: 26 Juni 2019
Menggantikan: NA
Disetujui oleh BPOM:

Diproduksi oleh:
Pfizer Italia S.r.l., Ascoli, Italia

Diimpor oleh:
PT. Pfizer Indonesia
Jakarta, Indonesia

17. Tanggal revisi
02/2022

Document Approval Record

Document Name:

PIL (Indonesian)_methylprednisolone _Medrol_Indonesia_CDS June 26, 2019

Document Title:

1st version, BPOM query in May 2021 & Aug 2021 & Nov 2021 & Jan 2022

Signed By:

Date(GMT)

Signing Capacity

Nurhayati, R. lin

11-Feb-2022 13:12:48

Final Approval